A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza (ANCHOR)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications
Sponsor: Cidara Therapeutics Inc.
Listed as NCT07159763, this PHASE3 trial focuses on Influenza and remains ongoing. Sponsored by Cidara Therapeutics Inc., it has been updated 5 times since 2025, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE3
-
Jan 2026 — Feb 2026 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE3
-
Nov 2025 — Dec 2025 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Oct 2025 — Nov 2025 [monthly]
Not Yet Recruiting PHASE3
First recorded
Sep 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cidara Therapeutics Inc.
For direct contact, visit the study record on ClinicalTrials.gov .